Fatty Acid Quality and Overweight (FO-study)

Weight Reduction and Insulin Sensitivity Clinical Trial

Official title:

Fatty Acid Quality and Overweight

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01034436
• Other study ID #: 6.2008.1368
• Status: Completed
• Phase: N/A
• First received: December 16, 2009
• Last updated: June 17, 2015
• Start date: February 2009

Study information

• Verified date: June 2015
• Source: Oslo and Akershus University College of Applied Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Norway:Regional Committees for Medical and Health Research Ethics
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to study the health effects of fatty acid quality in healthy, overweight individuals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. primary completion date: June 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• no use of medication, healthy, 27<BMI<40

Exclusion Criteria:

• pregnant and lactating women, chronic diseases.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Weight Loss
• Weight Reduction and Insulin Sensitivity

Intervention

Dietary Supplement:
• fatty acid quality and overweight
Duration 12 weeks

Locations

Country	Name	City	State
Norway	Akershus University College	Oslo	Lillestrom

Sponsors (1)

Lead Sponsor	Collaborator
Oslo and Akershus University College of Applied Sciences

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Will intake of fat as diacylglycerols give weight reduction in overweight individuals?		baseline (0 weeks), 12 weeks	No
Secondary	Will a high intake of ALA involve reduced levels of inflammatory markers?		baseline (0 weeks), 12 weeks	No
Secondary	Will a high intake of ALA involve changes in insulin sensitivity?		baseline (0 weeks), 12 weeks	No